ImmunityBio, Inc.
IBRX
$2.38
$0.135.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 60.04% | 129.10% | |||
| Total Other Revenue | -50.00% | -97.69% | |||
| Total Revenue | 59.99% | 118.71% | |||
| Cost of Revenue | 134.48% | -- | |||
| Gross Profit | 59.72% | 117.94% | |||
| SG&A Expenses | 29.07% | -21.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.71% | 5.19% | |||
| Operating Income | -10.64% | 7.16% | |||
| Income Before Tax | 28.94% | -119.50% | |||
| Income Tax Expenses | 214.96% | -- | |||
| Earnings from Continuing Operations | 28.61% | -119.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -5.00% | 17.65% | |||
| Net Income | 28.61% | -119.14% | |||
| EBIT | -10.64% | 7.16% | |||
| EBITDA | -11.23% | 7.14% | |||
| EPS Basic | 31.45% | -88.35% | |||
| Normalized Basic EPS | 31.76% | -90.58% | |||
| EPS Diluted | 31.45% | -62.92% | |||
| Normalized Diluted EPS | 31.76% | -90.96% | |||
| Average Basic Shares Outstanding | 4.11% | 16.36% | |||
| Average Diluted Shares Outstanding | 4.11% | 16.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||